This study focuses on ovarian cancer, specifically examining treatments for patients with HER2-expressing forms of the disease. The research evaluates two medications: trastuzumab deruxtecan (also known as DS-8201a) in combination with bevacizumab, compared to bevacizumab alone. These medications are given through an intravenous infusion, which means they are administered directly into a vein.

The purpose of this research is to determine if using these two medications together is more effective than using bevacizumab by itself in treating ovarian cancer. The study specifically looks at patients who have recently been diagnosed with advanced stages of the disease. Both medications are types of targeted therapy – bevacizumab works by affecting blood vessel growth in tumors, while trastuzumab deruxtecan is an antibody-drug conjugate that specifically targets cancer cells expressing the HER2 protein.

During the study, patients will receive treatment for up to 24 months. The medications will be given through regular infusions at specified intervals. Throughout the treatment period, doctors will monitor patients’ responses to the therapy and track any changes in their condition. This research is particularly focused on patients whose cancer shows specific levels of a protein called HER2 on their tumor cells.